DDInter596 DDInter462
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) upregulates {v} (Gene) PECR
PECR {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) downregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) downregulates {v} (Gene) NCAPH
NCAPH {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) CBR3
CBR3 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) upregulates {v} (Gene) CTSL
CTSL {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is regulated by {v} (Gene) SIK1
SIK1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Doxorubicin (Compound) upregulates PECR (Gene) and PECR (Gene) is upregulated by Dabrafenib (Compound)
Doxorubicin (Compound) downregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Dabrafenib (Compound)
Doxorubicin (Compound) downregulates NCAPH (Gene) and NCAPH (Gene) is downregulated by Dabrafenib (Compound)
Doxorubicin (Compound) binds CBR3 (Gene) and Doxorubicin (Compound) downregulates CBR3 (Gene) and CBR3 (Gene) is downregulated by Dabrafenib (Compound)
Doxorubicin (Compound) upregulates CTSL (Gene) and CTSL (Gene) is downregulated by Dabrafenib (Compound)
Doxorubicin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Doxorubicin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is regulated by SIK1 (Gene) and SIK1 (Gene) is bound by Dabrafenib (Compound)
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib